[
    {
        "molecule_name": "CD154",
        "protein_target_name": "CD154",
        "binding_metric": "IC50",
        "value": "20pM-1.5 μM",
        "unit": "pM-μM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nConjugated protein and the anti-CD154 antibody of CD154 of the present invention (comprising antibody fragment and derivative) is combined with usefulness and specificity height for what suppress CD154 and CD40, for example has 20pM-1.5 μ M(and comprises end points) IC50.\nIn certain embodiments, CD154 of the present invention conjugated protein (for example anti-CD154 antibody) can have the IC50 of 20pm-500pm, 50pm-500pm or 100pm-500pm.\nFor example, in certain embodiments, as (for example, by surface plasma body resonant vibration) record CD154 conjugated protein (for example anti-CD154 antibody) and comprise end points with 50nM-1pM() and K<sub>D</sub>Dissociate with human CD 154 (human CD 40 L).\nFor example, the K of human CD 154<sub>D</sub>Can be 50pm-1pm, 20pm-1pm or even 10pm-1pm.\nIn some embodiments, the K of human CD 154<sub>D</sub>Less than 20pM.\nIn other embodiments, the K of human CD 154<sub>D</sub>Less than 10pM."
    },
    {
        "molecule_name": "CD154",
        "protein_target_name": "CD154",
        "binding_metric": "IC50",
        "value": "20pm-500pm",
        "unit": "pm",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nConjugated protein and the anti-CD154 antibody of CD154 of the present invention (comprising antibody fragment and derivative) is combined with usefulness and specificity height for what suppress CD154 and CD40, for example has 20pM-1.5 μ M(and comprises end points) IC50.\nIn certain embodiments, CD154 of the present invention conjugated protein (for example anti-CD154 antibody) can have the IC50 of 20pm-500pm, 50pm-500pm or 100pm-500pm.\nFor example, in certain embodiments, as (for example, by surface plasma body resonant vibration) record CD154 conjugated protein (for example anti-CD154 antibody) and comprise end points with 50nM-1pM() and K<sub>D</sub>Dissociate with human CD 154 (human CD 40 L).\nFor example, the K of human CD 154<sub>D</sub>Can be 50pm-1pm, 20pm-1pm or even 10pm-1pm.\nIn some embodiments, the K of human CD 154<sub>D</sub>Less than 20pM.\nIn other embodiments, the K of human CD 154<sub>D</sub>Less than 10pM."
    },
    {
        "molecule_name": "CD154",
        "protein_target_name": "CD154",
        "binding_metric": "IC50",
        "value": "50pm-500pm",
        "unit": "pm",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nConjugated protein and the anti-CD154 antibody of CD154 of the present invention (comprising antibody fragment and derivative) is combined with usefulness and specificity height for what suppress CD154 and CD40, for example has 20pM-1.5 μ M(and comprises end points) IC50.\nIn certain embodiments, CD154 of the present invention conjugated protein (for example anti-CD154 antibody) can have the IC50 of 20pm-500pm, 50pm-500pm or 100pm-500pm.\nFor example, in certain embodiments, as (for example, by surface plasma body resonant vibration) record CD154 conjugated protein (for example anti-CD154 antibody) and comprise end points with 50nM-1pM() and K<sub>D</sub>Dissociate with human CD 154 (human CD 40 L).\nFor example, the K of human CD 154<sub>D</sub>Can be 50pm-1pm, 20pm-1pm or even 10pm-1pm.\nIn some embodiments, the K of human CD 154<sub>D</sub>Less than 20pM.\nIn other embodiments, the K of human CD 154<sub>D</sub>Less than 10pM."
    },
    {
        "molecule_name": "CD154",
        "protein_target_name": "CD154",
        "binding_metric": "IC50",
        "value": "100pm-500pm",
        "unit": "pm",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nConjugated protein and the anti-CD154 antibody of CD154 of the present invention (comprising antibody fragment and derivative) is combined with usefulness and specificity height for what suppress CD154 and CD40, for example has 20pM-1.5 μ M(and comprises end points) IC50.\nIn certain embodiments, CD154 of the present invention conjugated protein (for example anti-CD154 antibody) can have the IC50 of 20pm-500pm, 50pm-500pm or 100pm-500pm.\nFor example, in certain embodiments, as (for example, by surface plasma body resonant vibration) record CD154 conjugated protein (for example anti-CD154 antibody) and comprise end points with 50nM-1pM() and K<sub>D</sub>Dissociate with human CD 154 (human CD 40 L).\nFor example, the K of human CD 154<sub>D</sub>Can be 50pm-1pm, 20pm-1pm or even 10pm-1pm.\nIn some embodiments, the K of human CD 154<sub>D</sub>Less than 20pM.\nIn other embodiments, the K of human CD 154<sub>D</sub>Less than 10pM."
    },
    {
        "molecule_name": "CD154",
        "protein_target_name": "CD154",
        "binding_metric": "Kd",
        "value": "50nM-1pM",
        "unit": "nM-pM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nConjugated protein and the anti-CD154 antibody of CD154 of the present invention (comprising antibody fragment and derivative) is combined with usefulness and specificity height for what suppress CD154 and CD40, for example has 20pM-1.5 μ M(and comprises end points) IC50.\nIn certain embodiments, CD154 of the present invention conjugated protein (for example anti-CD154 antibody) can have the IC50 of 20pm-500pm, 50pm-500pm or 100pm-500pm.\nFor example, in certain embodiments, as (for example, by surface plasma body resonant vibration) record CD154 conjugated protein (for example anti-CD154 antibody) and comprise end points with 50nM-1pM() and K<sub>D</sub>Dissociate with human CD 154 (human CD 40 L).\nFor example, the K of human CD 154<sub>D</sub>Can be 50pm-1pm, 20pm-1pm or even 10pm-1pm.\nIn some embodiments, the K of human CD 154<sub>D</sub>Less than 20pM.\nIn other embodiments, the K of human CD 154<sub>D</sub>Less than 10pM."
    },
    {
        "molecule_name": "antibody 342",
        "protein_target_name": "CD40",
        "binding_metric": "IC50",
        "value": "<sub>d</sub>",
        "unit": null,
        "is_logarithmic": false,
        "raw_mentions": "Figure 12 lists by selecting the table of the isolating rat anti human CD 154 of lymphocyte antibody method (SLAM) antibody.This table shows and exists with these antibody, CD40 binding assay and ICAM-1 raise the K that obtains in the assay method <sub>d</sub>And IC<sub>50</sub>Value.The data that obtain with antibody 342 highlight.\nFigure 18 is the different embodiments that shows humanization 342gL4gH1 antibody (comprising Fab ' fragment and antibody-PEG conjugate),, CD40 binding assay, ICAM-1 raise the K that obtains in assay method and the CD40L competition binding assay <sub>d</sub>And IC<sub>50</sub>The table of value."
    },
    {
        "molecule_name": "CD154",
        "protein_target_name": "CD154",
        "binding_metric": "IC50",
        "value": "10pM-1.5 μM",
        "unit": "pM, μM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nTherefore, in certain embodiments, the conjugated protein and anti-CD154 antibody of CD154 of the present invention (comprising antibody fragment and derivative) is for the IC50 that is combined with usefulness and specificity height (for example 10pM-1.5 μ M(comprises end points) that suppresses CD154 and CD40).\nIn certain embodiments, CD154 of the present invention conjugated protein (for example antibody) can have the IC50 of 10pm-500pm, 50pm-500pm, 100pm-500pm, 250pm-750pm, 500pm-1 μ M or 750pm-1.5 μ M.\nFor example, if using this antibody in the vitro efficacy assay method as described in example 7 above, then can not demonstrate any significant basically antagonistic action, maybe can demonstrate with positive control (for example CD154 part) and compare 1%, 2%, 3%, 5% or 10% antagonistic action above control treatment."
    },
    {
        "molecule_name": "CD154",
        "protein_target_name": "CD154",
        "binding_metric": "IC50",
        "value": "10pm-500pm",
        "unit": "pm",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nTherefore, in certain embodiments, the conjugated protein and anti-CD154 antibody of CD154 of the present invention (comprising antibody fragment and derivative) is for the IC50 that is combined with usefulness and specificity height (for example 10pM-1.5 μ M(comprises end points) that suppresses CD154 and CD40).\nIn certain embodiments, CD154 of the present invention conjugated protein (for example antibody) can have the IC50 of 10pm-500pm, 50pm-500pm, 100pm-500pm, 250pm-750pm, 500pm-1 μ M or 750pm-1.5 μ M.\nFor example, if using this antibody in the vitro efficacy assay method as described in example 7 above, then can not demonstrate any significant basically antagonistic action, maybe can demonstrate with positive control (for example CD154 part) and compare 1%, 2%, 3%, 5% or 10% antagonistic action above control treatment."
    },
    {
        "molecule_name": "CD154",
        "protein_target_name": "CD154",
        "binding_metric": "IC50",
        "value": "50pm-500pm",
        "unit": "pm",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nTherefore, in certain embodiments, the conjugated protein and anti-CD154 antibody of CD154 of the present invention (comprising antibody fragment and derivative) is for the IC50 that is combined with usefulness and specificity height (for example 10pM-1.5 μ M(comprises end points) that suppresses CD154 and CD40).\nIn certain embodiments, CD154 of the present invention conjugated protein (for example antibody) can have the IC50 of 10pm-500pm, 50pm-500pm, 100pm-500pm, 250pm-750pm, 500pm-1 μ M or 750pm-1.5 μ M.\nFor example, if using this antibody in the vitro efficacy assay method as described in example 7 above, then can not demonstrate any significant basically antagonistic action, maybe can demonstrate with positive control (for example CD154 part) and compare 1%, 2%, 3%, 5% or 10% antagonistic action above control treatment."
    },
    {
        "molecule_name": "CD154",
        "protein_target_name": "CD154",
        "binding_metric": "IC50",
        "value": "100pm-500pm",
        "unit": "pm",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nTherefore, in certain embodiments, the conjugated protein and anti-CD154 antibody of CD154 of the present invention (comprising antibody fragment and derivative) is for the IC50 that is combined with usefulness and specificity height (for example 10pM-1.5 μ M(comprises end points) that suppresses CD154 and CD40).\nIn certain embodiments, CD154 of the present invention conjugated protein (for example antibody) can have the IC50 of 10pm-500pm, 50pm-500pm, 100pm-500pm, 250pm-750pm, 500pm-1 μ M or 750pm-1.5 μ M.\nFor example, if using this antibody in the vitro efficacy assay method as described in example 7 above, then can not demonstrate any significant basically antagonistic action, maybe can demonstrate with positive control (for example CD154 part) and compare 1%, 2%, 3%, 5% or 10% antagonistic action above control treatment."
    },
    {
        "molecule_name": "CD154",
        "protein_target_name": "CD154",
        "binding_metric": "IC50",
        "value": "250pm-750pm",
        "unit": "pm",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nTherefore, in certain embodiments, the conjugated protein and anti-CD154 antibody of CD154 of the present invention (comprising antibody fragment and derivative) is for the IC50 that is combined with usefulness and specificity height (for example 10pM-1.5 μ M(comprises end points) that suppresses CD154 and CD40).\nIn certain embodiments, CD154 of the present invention conjugated protein (for example antibody) can have the IC50 of 10pm-500pm, 50pm-500pm, 100pm-500pm, 250pm-750pm, 500pm-1 μ M or 750pm-1.5 μ M.\nFor example, if using this antibody in the vitro efficacy assay method as described in example 7 above, then can not demonstrate any significant basically antagonistic action, maybe can demonstrate with positive control (for example CD154 part) and compare 1%, 2%, 3%, 5% or 10% antagonistic action above control treatment."
    },
    {
        "molecule_name": "CD154",
        "protein_target_name": "CD154",
        "binding_metric": "IC50",
        "value": "500pm-1 μM",
        "unit": "pm, μM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nTherefore, in certain embodiments, the conjugated protein and anti-CD154 antibody of CD154 of the present invention (comprising antibody fragment and derivative) is for the IC50 that is combined with usefulness and specificity height (for example 10pM-1.5 μ M(comprises end points) that suppresses CD154 and CD40).\nIn certain embodiments, CD154 of the present invention conjugated protein (for example antibody) can have the IC50 of 10pm-500pm, 50pm-500pm, 100pm-500pm, 250pm-750pm, 500pm-1 μ M or 750pm-1.5 μ M.\nFor example, if using this antibody in the vitro efficacy assay method as described in example 7 above, then can not demonstrate any significant basically antagonistic action, maybe can demonstrate with positive control (for example CD154 part) and compare 1%, 2%, 3%, 5% or 10% antagonistic action above control treatment."
    },
    {
        "molecule_name": "CD154",
        "protein_target_name": "CD154",
        "binding_metric": "IC50",
        "value": "750pm-1.5 μM",
        "unit": "pm, μM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nTherefore, in certain embodiments, the conjugated protein and anti-CD154 antibody of CD154 of the present invention (comprising antibody fragment and derivative) is for the IC50 that is combined with usefulness and specificity height (for example 10pM-1.5 μ M(comprises end points) that suppresses CD154 and CD40).\nIn certain embodiments, CD154 of the present invention conjugated protein (for example antibody) can have the IC50 of 10pm-500pm, 50pm-500pm, 100pm-500pm, 250pm-750pm, 500pm-1 μ M or 750pm-1.5 μ M.\nFor example, if using this antibody in the vitro efficacy assay method as described in example 7 above, then can not demonstrate any significant basically antagonistic action, maybe can demonstrate with positive control (for example CD154 part) and compare 1%, 2%, 3%, 5% or 10% antagonistic action above control treatment."
    }
]